Study wrapper · #1064
Dose-dependent effects of oral semaglutide on arterial stiffness and the additive role of SGLT-2 inhibitors in type 2 diabetes.
Editor's note
This single-centre retrospective cohort reports a dose-dependent association between oral semaglutide and improved arterial stiffness (CAVI), amplified by concomitant SGLT-2 inhibitor use. Because the design is observational and retrospective, the findings are associations rather than causal effects, and the difference in downstream cardiovascular events did not reach statistical significance. Read the results as supportive but preliminary evidence on a surrogate vascular marker.
Plain-language abstract
In a retrospective cohort of 138 people with type 2 diabetes, higher-dose oral semaglutide was associated with improved arterial stiffness over six months, with a larger effect when combined with SGLT-2 inhibitors. This was an observational study, and a reduction in cardiovascular events was not demonstrated.